18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevaclzumab-based therapy

Chiara Funaioli, Carmine Pinto, Francesca Di Fabio, Donatella Santini, Claudio Ceccarelli, Emilio De Raffaele, Stefano Fanti, Paolo Castellucci, Ciro Longobardi, Federico Buggi, Andrea Angelo Martoni

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Around 20-30% of patients with hepatic metastasis from colorectal cancer can undergo liver resection, but the increased response rate obtained with the addition of monoclonal antibodies to chemotherapy regimens could result in a higher rate of liver surgery. In this report we describe the case of a patient who underwent a liver resection after neoadjuvant treatment with capecitabine, oxaliplatin and bevacizumab and who achieved a complete pathological response of the liver metastasis. A preoperative CT scan demonstrated a partial response to the treatment while 18FDG-PET scan correctly evaluated the complete pathological response in the liver and detected an active interaortocaval lymph node metastasis. New specific studies are required to evaluate the imaging response in metastatic colorectal cancer patients especially after treatment with new, targeted agents.

Original languageEnglish
Pages (from-to)611-615
Number of pages5
JournalTumori
Volume93
Issue number6
Publication statusPublished - Nov 2007

Fingerprint

Fluorodeoxyglucose F18
Colonic Neoplasms
Liver
oxaliplatin
Neoplasm Metastasis
Colorectal Neoplasms
Therapeutics
Neoadjuvant Therapy
Positron-Emission Tomography
Lymph Nodes
Monoclonal Antibodies
Drug Therapy

Keywords

  • Bevacizumab
  • Colorectal cancer
  • Liver metastases
  • PET

ASJC Scopus subject areas

  • Cancer Research

Cite this

Funaioli, C., Pinto, C., Di Fabio, F., Santini, D., Ceccarelli, C., De Raffaele, E., ... Martoni, A. A. (2007). 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevaclzumab-based therapy. Tumori, 93(6), 611-615.

18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevaclzumab-based therapy. / Funaioli, Chiara; Pinto, Carmine; Di Fabio, Francesca; Santini, Donatella; Ceccarelli, Claudio; De Raffaele, Emilio; Fanti, Stefano; Castellucci, Paolo; Longobardi, Ciro; Buggi, Federico; Martoni, Andrea Angelo.

In: Tumori, Vol. 93, No. 6, 11.2007, p. 611-615.

Research output: Contribution to journalArticle

Funaioli, C, Pinto, C, Di Fabio, F, Santini, D, Ceccarelli, C, De Raffaele, E, Fanti, S, Castellucci, P, Longobardi, C, Buggi, F & Martoni, AA 2007, '18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevaclzumab-based therapy', Tumori, vol. 93, no. 6, pp. 611-615.
Funaioli, Chiara ; Pinto, Carmine ; Di Fabio, Francesca ; Santini, Donatella ; Ceccarelli, Claudio ; De Raffaele, Emilio ; Fanti, Stefano ; Castellucci, Paolo ; Longobardi, Ciro ; Buggi, Federico ; Martoni, Andrea Angelo. / 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevaclzumab-based therapy. In: Tumori. 2007 ; Vol. 93, No. 6. pp. 611-615.
@article{5a7315014eea4b40bbfa09d715b4648a,
title = "18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevaclzumab-based therapy",
abstract = "Around 20-30{\%} of patients with hepatic metastasis from colorectal cancer can undergo liver resection, but the increased response rate obtained with the addition of monoclonal antibodies to chemotherapy regimens could result in a higher rate of liver surgery. In this report we describe the case of a patient who underwent a liver resection after neoadjuvant treatment with capecitabine, oxaliplatin and bevacizumab and who achieved a complete pathological response of the liver metastasis. A preoperative CT scan demonstrated a partial response to the treatment while 18FDG-PET scan correctly evaluated the complete pathological response in the liver and detected an active interaortocaval lymph node metastasis. New specific studies are required to evaluate the imaging response in metastatic colorectal cancer patients especially after treatment with new, targeted agents.",
keywords = "Bevacizumab, Colorectal cancer, Liver metastases, PET",
author = "Chiara Funaioli and Carmine Pinto and {Di Fabio}, Francesca and Donatella Santini and Claudio Ceccarelli and {De Raffaele}, Emilio and Stefano Fanti and Paolo Castellucci and Ciro Longobardi and Federico Buggi and Martoni, {Andrea Angelo}",
year = "2007",
month = "11",
language = "English",
volume = "93",
pages = "611--615",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevaclzumab-based therapy

AU - Funaioli, Chiara

AU - Pinto, Carmine

AU - Di Fabio, Francesca

AU - Santini, Donatella

AU - Ceccarelli, Claudio

AU - De Raffaele, Emilio

AU - Fanti, Stefano

AU - Castellucci, Paolo

AU - Longobardi, Ciro

AU - Buggi, Federico

AU - Martoni, Andrea Angelo

PY - 2007/11

Y1 - 2007/11

N2 - Around 20-30% of patients with hepatic metastasis from colorectal cancer can undergo liver resection, but the increased response rate obtained with the addition of monoclonal antibodies to chemotherapy regimens could result in a higher rate of liver surgery. In this report we describe the case of a patient who underwent a liver resection after neoadjuvant treatment with capecitabine, oxaliplatin and bevacizumab and who achieved a complete pathological response of the liver metastasis. A preoperative CT scan demonstrated a partial response to the treatment while 18FDG-PET scan correctly evaluated the complete pathological response in the liver and detected an active interaortocaval lymph node metastasis. New specific studies are required to evaluate the imaging response in metastatic colorectal cancer patients especially after treatment with new, targeted agents.

AB - Around 20-30% of patients with hepatic metastasis from colorectal cancer can undergo liver resection, but the increased response rate obtained with the addition of monoclonal antibodies to chemotherapy regimens could result in a higher rate of liver surgery. In this report we describe the case of a patient who underwent a liver resection after neoadjuvant treatment with capecitabine, oxaliplatin and bevacizumab and who achieved a complete pathological response of the liver metastasis. A preoperative CT scan demonstrated a partial response to the treatment while 18FDG-PET scan correctly evaluated the complete pathological response in the liver and detected an active interaortocaval lymph node metastasis. New specific studies are required to evaluate the imaging response in metastatic colorectal cancer patients especially after treatment with new, targeted agents.

KW - Bevacizumab

KW - Colorectal cancer

KW - Liver metastases

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=38549145873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549145873&partnerID=8YFLogxK

M3 - Article

C2 - 18338499

AN - SCOPUS:38549145873

VL - 93

SP - 611

EP - 615

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -